Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
äŒæ¥ã³ãŒãLAB
äŒç€ŸåStandard BioTools Inc
äžå Žæ¥Feb 10, 2011
æé«çµå¶è²¬ä»»è
ãCEOãEgholm (Michael)
åŸæ¥å¡æ°818
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Feb 10
æ¬ç€Ÿæåšå°2 Tower Place
éœåžSOUTH SAN FRANCISCO
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·94080
é»è©±çªå·16502666000
ãŠã§ããµã€ãhttps://www.standardbio.com/
äŒæ¥ã³ãŒãLAB
äžå Žæ¥Feb 10, 2011
æé«çµå¶è²¬ä»»è
ãCEOãEgholm (Michael)